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Abstract
Background: Tumor epithelial cells (TEpCs) and spindle-shaped stromal cells, not associated with the vasculature,
of patients with early breast cancer express osteoprotegerin (OPG), tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL), receptor activator of nuclear factor kappa B ligand, stromal cell derived factor-1, interleukin-6,
macrophage colony stimulating factor, chemokine (C-C motif) ligand-2 (CCL-2) and their receptors at significantly
higher levels compared with non-neoplastic breast tissues. We evaluated the clinicopathological significance of
these ligands and receptors in TEpC and spindle-shaped stromal cells, not associated with the vasculature, to
determine their impact on prognosis of patients with early-stage breast cancer.
Methods: We conducted immunohistochemical analyses of protein expression in primary tumors of patients with early
breast cancer and analyzed their association with standard prognostic parameters and clinical outcomes, including local
relapse, metastatic recurrence, disease-free survival (DFS), metastasis-free survival (MFS), and overall survival (OS).
Results: Elevated levels of TRAIL-R3 and chemokine (C-C motif) receptor 2 (CCR-2) in TEpCs and OPG and CCL-2 in
stromal cells were significantly associated with a higher risk of metastasis (p = 0.032, p = 0.003, p = 0.038, and p = 0.049;
respectively). Moreover, high expression of TRAIL-R3 and CCR-2 in TEpCs was associated with shorter DFS, MFS, and OS.
High TRAIL-R3 expression in TEpCs was an independent prognostic factor for DFS and OS, and high CCR-2 expression in
these cells was an independent prognostic factor for MFS.
Conclusions: High levels of TRAIL-R3 and CCR-2 expression in TEpCs identified patients with early breast cancer with
poor outcomes.
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Background
Breast cancer is the most common cancer among
women worldwide [1–4] and in Argentina affects more
than 25,000 women and causes more than 5000 deaths
each year (Bureau of Health Information Statistics and
Nation, Department of Statistics and Health Informa-
tion, Ministry of Health, Argentina, 2013). Distant
metastasis is the main cause of death in these patients
[5]. In high-income countries, breast cancer is usually
diagnosed early, and treatment with curative intent and
manageable toxicity is feasible. However, many women
experience recurrence despite receiving optimal therapy,
likely because the tumor microenvironment plays a key
role in the development of resistance to treatment [6].
Breast cancer tissue comprises tumor epithelial cells
(TEpCs) and stromal cells such as mesenchymal stem
cells, tumor-associated fibroblasts, fibroblasts, endothe-
lial cells, adipocytes, and immune cells. The interaction
of malignant and non-malignant cells influences tumori-
genesis, tumor growth, metastasis, and response to
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therapy [6–15]. Our group demonstrated that spindle-
shaped stromal cells are not associated with the
vasculature and TEpCs from primary invasive ductal
breast cancer in women with stage I or II express
molecules such as osteoprotegerin (OPG), tumor necro-
sis factor-related apoptosis-inducing ligand (TRAIL),
receptor activator of nuclear factor kappa B ligand
(RANKL), stromal cell derived factor (SDF)-1, interleu-
kin (IL)-6, chemokine (C-C motif ) ligand-2 (CCL-2) and
their receptors [15]. These molecules, which are likely
involved in the interactions between these cell types,
mediate proliferation, survival, migration, and intravasa-
tion of TEpCs as well as angiogenesis in the primary
tumor [15]. These findings led us to ask whether the
levels of expression of these ligand-receptor pairs are
useful for predicting the outcomes of patients with
stage I/II breast cancer.
Methods
Patients
We conducted a retrospective study of 63 consecutive
patients (aged 42–80 years) with a confirmed histological
diagnosis of breast cancer who underwent initial surgery
at the Hospital Italiano of Buenos Aires, Argentina.
Patients were included if they were diagnosed with stage
I/II invasive ductal breast cancer according to the
International Union Against Cancer TNM classification
system [16] and ≥10 years after surgery. Exclusion
criteria included neoadjuvant therapies, lack of tissue,
and another primary tumor. After surgery, all patients
were treated with the indicated therapy, depending on
their clinical status and the histopathological characteris-
tics of their tumor, which were determined according to
the recommendations of the European Society for
Medical Oncology [17]. The Instituto de Biología y Medi-
cina Experimental and the Hospital Italiano Ethics
Committees approved this study, and informed consent
was obtained from patients or the relatives of deceased pa-
tients, in accordance with the principles of the Helsinki
Declaration. Physicians who were unaware of the path-
ology results acquired clinical information from patients’
medical records, and the anonymity of the data was ensured
using a code made available only to the biostatistician.
Tumor samples
Breast tissues embedded in paraffin blocks and fixed in
10% neutral-buffered formalin were retrieved from the
surgical archives, and 4-μm thick sections were used in
the experiments described below.
Analysis of protein expression
These tissues were processed and immunohistochemistry
was used to determine the levels of ligands and receptors
in TEpC and in spindle-shaped stromal cells, not
associated with the vasculature, and it was completed as
described in a previously work [15].
Immunoreactivity was reviewed and scored independ-
ently by two pathologists who were blinded to patient out-
comes. In uncertain cases, re-evaluation was performed
using a double-headed microscope, and staining was
evaluated until a consensus was achieved. The agreement
in immunohistochemical evaluation between the two
observers was 91.77% (Cohen’s kappa coefficient = 0.895).
Each sample was assayed in duplicate and was initially
examined at 100× magnification followed by observation of
five representative fields at 400× magnification along a
projected Z-line. Expression levels were evaluated separ-
ately for the TEpCs and spindle-shaped stromal cells, not
associated to the vasculature, per the percentage of positive
cells and staining intensity, which were estimated according
to the Allred score [15, 16]. The percentages of positive
cells were assigned scores as follows: 0 (<10%), 1 (10%–
30%), 2 (31%–60%), 3 (61%–90%), and 4 (>90%). Staining
intensity was scored as 0 (no staining), 1 (weak), 2 (moder-
ate), and 3 (strong), according to the relative intensity of
staining of TEpCs analyzed using the anti-cytokeratin anti-
body [15, 18]. The final staining score was calculated using
the sum of the percentage of positive cells and the staining
intensity score, which ranged from 0 to 7. Stromal cells
included in this study had a spindle shape and were not as-
sociated with vasculature. CD34 expression was undetect-
able in this type of stromal cells as previously reported [18].
Patients’ clinicopathological characteristics
Classical prognostic markers were categorized according
to cut-offs used in the protocols of the Hospital Italiano,
[17] including: a) age < 50 or ≥50 years; b) tumor size
<2 or ≥2 cm; c) histological grade according to the
Scarff-Bloom-Richardson grading system [19], which is
expressed as differentiated (G1), intermediate (G2), and
poor (G3); d) expression of estrogen/progesterone recep-
tors and HER2/neu was defined as negative or positive
according to Wernicke et al. [17]; and e) presence of re-
gional metastatic lymph nodes was recorded as negative
(negative nodes in axillary dissection or sentinel lymph
node) or positive (including micrometastasis) (Table 1).
Statistical analysis
To evaluate the statistical significance of the associations
between the expression of ligand or receptor and
patients’ clinicopathological characteristics, we deter-
mined an optimal cut-off value according to a previous
study [18]. The cut-off value was used to assign protein
expression in tumor samples as negative/low or high. To
determine the optimal cut-off value, the first quartile
(Q1), median, and third quartile (Q3) values were tested
individually using univariate analysis and compared with
OS. The cut-off value with lowest p value was chosen.
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The optimal cut-off values for protein expression in
TEpCs were as follows: OPG = 6 (Q3), TRAIL =6 (Q3),
TRAIL-R1 = 0 (Q1), TRAIL-R2 = 6 (Q3), TRAIL-R3 = 5
(median), TRAIL-R4 = 5 (Q1), RANKL =3 (Q1),
RANK =6 (Q1), SDF-1 = 5 (Q1), CXCR-4 = 4 (Q1),
IL-6 = 4 (median), IL-6R = 6 (median), CCL-2 = 6 (Q3),
and chemokine (C-C motif) receptor 2 (CCR-2) = 6 (Q3).
The optimal cut-off values for protein expression in
spindle-shaped stromal cells, not associated with vascula-
ture, were as follows: OPG = 2 (median), TRAIL =4
(median), RANKL =2 (Q1), SDF-1 = 2 (Q1), IL-6 = 4
(Q3), and CCL-2 = 3 (Q3). We used Fisher’s exact test to
evaluate the association between the expression of these
proteins with classical prognostic markers as well as local
relapse and metastatic occurrence. Moreover, the associ-
ation between the ligand and receptor expressions in
TEpCs and spindle-shaped stromal cells and metastatic
occurrence is displayed as a heat map prepared using Excel.
DFS and MFS were defined as the interval from date of
surgery to the first observation of tumor occurrence
(metastatic occurrence and/or local relapse) and metastatic
occurrence, respectively, or last follow-up. The interval from
the date of surgery until death or last follow-up was defined
as OS. Univariate analyses of DFS, MFS, and OS were
performed using the Kaplan-Meier method, and the differ-
ences were evaluated using the log-rank (Mantel-Cox) test.
When significant variables were identified, we applied the
Cox proportional hazards model to the multivariate sur-
vival analysis using backward stepwise selection (likelihood
ratio) that incorporated only the significant variables. Statis-
tical analysis was performed using SSPS software (version
18.00, Chicago, Illinois) and InfoStat (version 2012, InfoStat
Group, National University of Cordoba, Argentina). A two-
sided p value <0.05 was considered statistically significant.
Results
Association of expression in TEpCs of OPG, TRAIL, RANKL,
SDF-1, IL-6, and CCL-2 with patients’ clinicopathological
characteristics
The expression of TRAIL was significantly associated with
lymph node status (Table 2). High TRAIL expression was
detected in 10/40 breast cancer patients with negative lymph
nodes, and TRAIL expression was undetectable in 0/16 of
patients with positive lymph nodes. SDF-1 expression was
significantly associated with tumor size and was high in
31/44 patients with tumors <2 cm and in 7/17 patients with
tumors ≥2 cm (p = 0.004, Table 2). High levels of CCL-2
expression were detected in some patients with negative
(3/15) or positive (1/42) ER expression (Table 2). The DFS of
patientswith high CCL-2 expressionwas 67.7 ± 32.0months,
compared with 123.15 ± 8.28 months for those with
low/negative CCL-2 expression (p = 0.048, Table 3).
Association of expression in TEpCs of TRAIL-R1–4, RANK,
CXCR-4, IL-6R, and CCR-2 with patients’ clinicopathological
characteristics
IL-6R expression in TEpCs was associated with age
(Table 4). Specifically, IL-6R expression was higher in 6/8
patients <50 years of age and in 15/48 patients ≥50 years of
Table 1 Clinical characteristics of 63 patients with early invasive
ductal breast cancer
Characteristics Patients (n) Patients (%)
Age (years)
< 50 10 15.9
≥ 50 53 84.1
Unknown - -
Tumor size (cm)
<2 45 71.4
≥ 2 17 27.0
Unknown 1 1.6
Histological grade
G1 15 23.8
G2 22 34.9
G3 24 38.1
Unknown 2 3.2
HER2/neu status
Negative 39 61.9
Positive 23 36.5
Unknown 1 1.6
ER status
Negative 15 23.8
Positive 47 74.6
Unknown 1 1.6
PR status
Negative 14 22.2
Positive 48 76.2
Unknown 1 1.6
Regional lymph nodes
Negative 44 69.8
Positive 16 25.4
Unknown 3 4.8
Local relapse
Negative 50 79.4
Positive 6 9.5
Unknown 7 11.1
Metastatic event
Non-metastasis 45 71.4
Metastasis 11 17.5
Unknown 7 11.1
Labovsky et al. BMC Cancer  (2017) 17:280 Page 3 of 12
Ta
b
le
2
A
ss
oc
ia
tio
n
of
th
e
le
ve
ls
of
ex
pr
es
si
on
of
O
PG
,T
RA
IL
,R
A
N
KL
,S
D
F-
1,
IL
-6
,a
nd
C
C
L-
2
in
TE
pC
s
w
ith
th
e
cl
in
ic
op
at
ho
lo
gi
ca
lc
ha
ra
ct
er
is
tic
s
of
pa
tie
nt
s
w
ith
ea
rly
in
va
si
ve
C
ha
ra
ct
er
is
tic
s
Li
ga
nd
s
in
TE
pC
O
PG
TR
A
IL
RA
N
KL
SD
F-
1
IL
-6
C
C
L-
2
H
ig
h
ex
pr
es
si
on
%
p
H
ig
h
ex
pr
es
si
on
%
p
H
ig
h
ex
pr
es
si
on
%
p
H
ig
h
ex
pr
es
si
on
%
p
H
ig
h
ex
pr
es
si
on
%
p
H
ig
h
ex
pr
es
si
on
%
p
A
ge
(y
ea
rs
)
<
50
10
.0
>
0.
99
9
2.
2
0.
65
7
70
.0
>
0.
99
9
40
.0
0.
15
3
22
.2
0.
46
4
22
.2
0.
11
0
≥
50
15
.7
16
.0
73
.1
67
.3
39
.2
4.
1
Tu
m
or
si
ze
(c
m
)
<
2
13
.9
>
0.
99
9
17
.1
>
0.
99
9
65
.9
0.
11
4
70
.4
0.
04
4*
42
.9
0.
23
6
7.
3
>
0.
99
9
≥
2
11
.8
17
.6
88
.2
41
.2
23
.5
6.
2
H
is
to
lo
gi
ca
lg
ra
de
G
1
20
.0
0.
71
3
21
.4
0.
74
4
46
.7
0.
07
3
80
.0
0.
09
3
42
.9
0.
30
7
6.
7
0.
35
7
G
2
10
.0
20
.0
80
.9
66
.7
45
.0
0.
0
G
3
12
.5
13
.0
79
.2
45
.8
25
.0
13
.0
H
ER
2/
ne
u
st
at
us
N
eg
at
iv
e
8.
1
0.
23
9
18
.9
0.
73
3
76
.3
0.
38
8
63
.2
>
0.
99
9
39
.5
0.
78
0
2.
9
0.
28
7
Po
si
tiv
e
21
.7
14
.3
65
.2
60
.9
33
.3
3
13
.6
ER
st
at
us
N
eg
at
iv
e
13
.3
>
0.
99
9
7.
7
0.
42
9
80
.0
0.
52
3
40
.0
0.
06
4
42
.9
0.
75
3
20
.0
0.
04
9*
Po
si
tiv
e
13
.3
20
.0
69
.6
69
.6
35
.6
2.
4
PR
st
at
us
N
eg
at
iv
e
14
.3
>
0.
99
9
8.
3
0.
44
4
78
.6
0.
73
7
50
.0
0.
35
1
38
.5
>
0.
99
9
7.
1
>
0.
99
9
Po
si
tiv
e
13
.0
19
.6
70
.2
66
.0
37
.0
7.
0
Re
gi
on
al
ly
m
ph
no
de
s
N
eg
at
iv
e
11
.6
0.
66
6
25
.0
0.
04
8*
67
.4
0.
35
2
58
.1
0.
55
5
39
.0
0.
76
1
4.
7
0.
34
9
Po
si
tiv
e
20
.0
0.
0
81
.2
68
.7
31
.2
14
.3
M
et
as
ta
tic
oc
cu
rr
en
ce
N
eg
at
iv
e
20
.9
0.
18
0
21
.4
0.
66
4
70
.4
0.
70
7
59
.1
>
0.
99
9
30
.2
>
0.
99
9
2.
4
0.
10
9
Po
si
tiv
e
18
.2
10
.0
81
.8
63
.6
40
.0
18
.2
Lo
ca
lr
el
ap
se
N
eg
at
iv
e
6.
1
0.
33
0
20
.8
0.
57
6
70
.0
0.
30
7
60
.0
>
0.
99
9
38
.8
0.
28
4
4.
3
0.
26
6
Po
si
tiv
e
20
.0
0.
0
10
0.
0
60
.0
0.
0
20
.0
Labovsky et al. BMC Cancer  (2017) 17:280 Page 4 of 12
age (Table 4). Patients with high expression of
TRAIL-R3 and CCR-2 in TEpCs were at significantly
higher risk for metastatic tumors than patients with
low expression (Table 4). High levels of TRAIL-R3
were expressed in 7/11 breast cancer patients with
metastasis and in 12/45 patients with non-metastatic
tumors (p = 0.032, Table 4). Certain patients with
metastatic (5/11) or non-metastatic tumors (2/42)
expressed high levels of CCR-2 (Fig. 1 and Table 4).
There was an association of high TRAIL-R3 expres-
sion with shorter DFS, MFS, and OS (Table 3). The
values of DFS, MFS and OS of patients with high
TRAIL-R3 expression were as follows (months):
90.04 ± 14.64, 97.02 ± 14.08 and 112.75 ± 12.73,
respectively; for patients with low/negative expression
were 136.22 ± 7.52, 140.22 ± 6.61 and 146.51 ± 5.16,
respectively (Fig. 2 and Table 3).
Furthermore, there was an association of high
CCR-2 expression with shorter DFS, MFS and OS
(Table 3). The values of DFS, MFS, and OS of
patients with high CCR-2 expression were as fol-
lows (months): 87.57 ± 18.57, 87.71 ± 18.58, and
114.67 ± 15.29, respectively; for patients with
low/negative expression were 127.57 ± 8.42,
133.94 ± 7.52, and 140.44 ± 6.41, respectively (Fig. 3
and Table 3).
Association of expression in spindle-shaped stromal cells
of OPG, TRAIL, RANKL, SDF-1, IL-6, and CCL-2 with patients’
clinicopathological characteristics
SDF-1 expression in spindle-shaped stromal cells
was associated with histological grades, and high
SDF-1 expression was detected in 10/15, 14/21, and
8/24 patients with differentiation grades G1, G2,
Table 3 Univariate analysis of disease-free, metastasis-free, and overall survival of patients with early invasive ductal breast cancer
Univariate p-value
Disease-free survival Metastasis-free survival Overall survival
Age 0.598 0.448 0.500
Tumor size 0.113 0.020* 0.069
Histological grade 0.178 0.291 0.207
HER2/neu status 0.536 0.293 0.103
ER status 0.336 0.191 0.175
PR status 0.691 0.946 0.521
Regional lymph nodes 0.595 0.805 0.620
OPG/TEpC 0.167 0.052 0.178
TRAIL/TEpC 0.465 0.648 0.304
RANKL/TEpC 0.156 0.267 0.307
SDF-1/TEpC 0.660 0.932 0.710
IL-6/TEpC CCL-2 0.873 0.710 0.487
CCL-2/TEpC 0.048* 0.071 0.507
TRAIL-R1/TEpC 0.536 0.339 0.626
TRAIL-R2/TEpC 0.894 0.749 0.392
TRAIL-R3/TEpC 0.009* 0.012* 0.015*
TRAIL-R4/TEpC 0.186 0.131 0.478
RANK/TEpC 0.546 0.991 0.804
CXCR-4/TEpC 0.164 0.255 0.175
IL-6R/TEpC 0.391 0.540 0.626
CCR-2/TEpC 0.013* 0.002* 0.049*
OPG/stromal cells 0.318 0.101 0.441
TRAIL/stromal cells 0.284 0.084 0.337
RANKL/stromal cells 0.139 0.052 0.222
SDF-1/stromal cells 0.792 0.734 0.306
IL-6/stromal cells CCL-2 0.218 0.093 0.168
CCL-2/stromal cells 0.104 0.076 0.505
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Fig. 1 Heat map of the association of ligand and receptor expression in TEpCs and spindle-shaped stromal cells with metastasis. Graphic show
data for tumor samples with high and negative/low expression of ligand and receptor
Fig. 2 Association of TRAIL-R3 expression in TEpCs with DFS, MFS, and OS. Kaplan–Meier curves show representative data for tumor samples with
high and negative/low expression of TRAIL-R3 in TEpCs. Original magnification: 400×. Scale bars =50 μm
Labovsky et al. BMC Cancer  (2017) 17:280 Page 7 of 12
and G3, respectively (Table 5). In contrast, high
expression of OPG and CCL-2 in stromal cells was
associated with a higher risk of metastasis (Fig. 1
and Table 5). High expression of OPG was observed
in 7/10 patients with metastatic tumors and in
14/43 patients with non-metastatic tumors
(p = 0.038, Fig. 1 and Table 5). In patients with
metastatic or non-metastatic tumors, 4/11 and 4/44
expressed high levels of CCL-2, respectively (Fig. 1
and Table 5).
Univariate analysis of the association of classical
prognostic markers with DFS, MFS, and OS
Of clinical variables analyzed, only tumor size was associated
with MFS (Table 3). Patients with tumors >2 cm had earlier
metastasis compared with those with tumors ≤2 cm as fol-
lows (months): 93.00 ± 15.59 vs 139.02 ± 6.47, respectively.
Multivariate analysis
TRAIL-R3 expression in TEpCs was an independent
prognostic factor for DFS and OS (Table 6). Moreover,
Fig. 3 Association of CCR-2 expression in TEpCs with DFS, MFS, and OS. Images show representative data of tumor samples with high and negative/
low expression of CCR-2 in TEpCs. Original magnification: 400×. Scale bars =50 μm
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tumor size and CCR-2 expression were independent
prognostic factors for MFS (Table 6).
Discussion
Tumor progression is a multistep process involving in-
teractions between tumor cells and spindle-shaped stro-
mal cells, not associated with the vasculature, which
supply signals that may promote tumor progression [15].
Here we show that high TRAIL expression in TEpCs
was significantly associated with negative lymph-node
status. Paracrine signaling induced by the binding of
TRAIL to the death receptors TRAIL-R1 and TRAIL-R2
induces apoptosis [20–22]. Thus, the association of
TRAIL expression in TEpCs of patients with negative
lymph nodes might reflect the apoptotic effects of
TRAIL that delay tumor progression as well as the ex-
travasation of tumor cells to regional lymph nodes [23].
Patients with TEpCs that expressed high levels of
TRAIL-R3 harbored metastases and experienced shorter
DFS, MFS, and OS. TRAIL-R3 competes with TRAIL-
R1, TRAIL-R2, or both for the binding of TRAIL, which
inhibits apoptotic signaling [20]. Moreover, the expres-
sion of TRAIL-R3 in TEpCs was an independent prog-
nostic marker for DFS and OS. These findings indicate
the importance of evaluating TRAIL-R3 expression in
TEpCs, because TRAIL is used to treat tumors. Thus,
outcomes may be adversely affected by the level of
TRAIL-R3 activity in tumors as well as in the tumor
microenvironment.
In contrast, we found that high SDF-1 expression in
TEpCs was significantly associated with tumor size
<2 cm, which is consistent with the findings of previous
studies [24, 25]. Furthermore, high expression of SDF-1
in spindle-shaped stromal cells, not associated with the
vasculature, was significantly associated with conven-
tional prognostic markers of less adverse tumor pheno-
types, such as low histological grade (G1 and G2).
We show here that the expression of CCL-2 in TEpCs
was associated with negative ER-status, which agrees
with reports demonstrating that CCL-2 is overexpressed
in ER-negative compared with ER-positive tumors [26].
These data suggest the involvement of CCL-2 in the
progression of ER-negative breast tumors. Moreover
high CCL-2 expression in TEpCs was significantly
associated with DFS. CCL-2 directly promotes the malig-
nant phenotype (epithelial mesenchymal transition) of
TEpCs and increases their ability to migrate, proliferate,
and invade tissues [27–30]. Also, patients with high
CCR-2 expression in TEpCs experienced shorter DFS,
MFS, and OS. Furthermore, the expression of CCR-2 is
up-regulated in breast tumor cells, and knockdown of
CCR-2 expression inhibits breast tumor development
[31]. Additionally, we show here that CCR-2 expression
was an independent prognostic factor for MFS.
Stromal cells such as fibroblast that produce CCL-2
enhance the invasiveness and metastatic growth of hu-
man breast cancer cell lines [31], which is consistent
with the present findings of a significant association be-
tween high CCL-2 expressions in spindle-shaped stromal
cells in patients with metastatic early-stage breast can-
cer. Our data indicate the importance of evaluating
CCR-2 expression in TEpCs as well as CCL-2 expression
in TEpC and spindle-shaped stromal cells, because the
pathways that produce CCR-2 and its ligands may pro-
vide targets for the prevention of breast cancer progres-
sion and metastasis [29]. Interestingly, we found
previously that the expression of CCL-2 in spindle-
shaped stromal cells, not associated with the vascula-
ture, correlated positively with the expression of CCR-2
in TEpCs, suggesting that CCL-2 signaling through
CCR-2 may contribute to the interactions between
TEpCs and spindle-shaped stromal cells, which en-
hance the malignant phenotype of tumor cells during
the early stages of disease [15].
We uncovered a significant association between high
OPG expression in spindle-shaped stromal cells and the
presence of metastatic breast tumors. This finding is
consistent with those showing that OPG produced by a
breast tumor induces angiogenesis and inhibits TRAIL-
mediated apoptosis to promote the growth of the pri-
mary tumor as well as metastatic cells [32, 33].
To our knowledge, this study is the first to demon-
strate that high expression of TRAIL-R3 and CCR-2 in
TEpCs serves as a prognostic marker of metastatic tu-
mors as well as DFS, MFS, and OS in women with stage
I/II invasive breast cancer. These new findings provide a
rationale for further studies designed to target TRAIL-
R3 and CCR-2 signaling pathways to facilitate the diag-
nosis, prevention, and treatment of breast cancer.
Conclusions
High levels of TRAIL-R3 and CCR-2 expression in
TEpCs identified early breast cancer patients with poor
outcomes, including a higher risk of metastasis and
shorter DFS, MFS, and OS and represent new inde-
pendent prognostic factors that may also be suitable
therapeutic targets.
Table 6 Multivariate analysis of DFS, MFS, and OS of patients
with early invasive ductal breast cancer
Variables HR 95% CI p
Disease-free survival TRAIL-R3 in TEpC 3.566 1.164–10.920 0.026
Metastasis-free survival Tumor size 8.210 2.013–33.477 0.003
CCR-2 in TEpC 10.257 2.569–40.947 0.001
Overall survival TRAIL-R3 in TEpC 5.741 1.113–29.621 0.037
C.I. confidence interval, HR hazard ratio
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